key: cord-0756600-up71ftfy
authors: Mametja, S.; Dessie, Zelalem G.; Matoti, L.; Semenya, M.; Moloabi, S.; Essack, S. Y.
title: Clinical Management of COVID-19 in Hospitals and the Community: A Snapshot from a Medical Insurance Database in South Africa
date: 2022-04-22
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2022.04.032
sha: 2d5b1a5952240b0b9c8439df531a746d01e443d5
doc_id: 756600
cord_uid: up71ftfy

Background : Little is known about the clinical care, utilisation of medicines and risk factors associated with mortality amongst the private health insured population with COVID-19 in South Africa. Methods : This was a retrospective cross-sectional study using claims data of patients with confirmed COVID-19. Socio-demographics, comorbidities, severity, concurrent/progressive comorbidity, drug treatment, and outcomes were extracted from administrative data. Univariate and multivariate logistic regression models were used to explore the risk factors associated with in-hospital death. Results : This study included 154 519 patients with COVID-19, only 24% were categorised as severe as they received in-hospital care. Antibiotics (42.8%) and steroids (30%) use was high in this population. After adjusting for known comorbidities, concurrent/progressive diagnosis, of the following conditions was associated with higher in-hospital death odds: ARDS [aOR=1•55; 95% CI=1.44-1.68], septic shock [aOR=1.55 95% CI=2.00-4.12], pneumonia [aOR=1.35; 95% CI=1.24-1.47], acute renal failure [aOR=; 95% CI=2.09-2.5] and stroke [aOR=2.09; 95% CI=1.75-2.49]). Use of antivirals (aOR=0•47; 95% CI= 0.40-0.54),) and/or steroids [aOR=0•46; 95% CI=0.43-0.50] was associated with decreased death odds. The use of antibiotic in-hospital was not associated with increased survival [aOR=0.97; 95% CI=0.91-1.04]. Conclusion : Comorbidities remain significant risk factors of death mediated by organ failure. The use of antibiotics did not change the odds of death, suggesting inappropriate use. Funding : None

Since the first report of the coronavirus disease 2019 , caused by the novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), in Wuhan, China, in December 2019 (World Health Organization, 2020) there have been 378 460 745 cases and 5 674 493 deaths globally as at 02 February 2022. (Johns Hopkins University of Medicine, 2021) COVID-19 is a viral respiratory tract infection with clinical manifestations ranging from asymptomatic and mild cases to critical cases. The vast majority of patients develop mild (40%) or moderate (40%) disease, approximately 15% develop severe disease requiring oxygen support, and 5% have critical disease characterised by complications, such as respiratory failure, acute respiratory distress syndrome (ARDS), sepsis and septic shock, thromboembolism, and/or multi-organ failure, including acute kidney injury and cardiac injury. (World Health Organization, 2020) Adulthood, male gender, older age, location in urban and deprived areas, and smoking are demographic and lifestyle risk factors for the disease. (de Lusignan et al., 2020) Underlying non-communicable diseases (NCDs), such as diabetes, hypertension, cardiac disease, chronic lung disease, cerebrovascular disease, chronic kidney disease, immune suppression, and cancer, are clinical risk factors for severe disease and death. (World Health Organization, 2020) Mild cases are managed by self-isolation, the use of masks, good hygiene practices, and symptomatic treatment, such as antipyretics, analgesics, and appropriate rehydration.

Antibiotic treatment or prophylaxis is explicitly not recommended. Moderate COVID-19 cases with suspected viral pneumonia are similarly managed, at-risk populations may require hospitalisation, and antibiotics are only recommended on clinical suspicion or ideally laboratory confirmation of secondary bacterial infection. Escalation of medical care is recommended where there is clinical deterioration. The management of severe pneumonia in severe COVID-19 requires immediate administration of supplemental oxygen, cautious fluid management, and close monitoring for clinical deterioration with appropriate supportive care.

Empiric antimicrobial treatment covering all likely pathogens is recommended on the basis of clinical judgment, patient host factors, and local epidemiology. Antimicrobials should be administered as soon as possible (within 1 hour of initial assessment), ideally with blood cultures obtained first and assessed daily thereafter for de-escalation. Non-invasive ventilation is recommended in the first instance for ARDS management in critical COVID-19 cases, followed by advanced oxygen/ventilator support upon acute hypoxemic respiratory failure, and conservative fluid management. The management of septic shock in critical COVID-19 cases requires crystalloid fluid and vasopressors for resuscitation. Antimalarials, antivirals, immunomodulators, and convalescent plasma therapy are explicitly discouraged outside of clinical trials. (World Health Organization, 2020) Notwithstanding World Health Organization (WHO) guidance, and despite minimal robust evidence to support their use of antivirals, (Cao et al., 2020) antimalarials, (Touret & de Lamballerie, 2020) and antibiotics (Molina et al., 2020) singly and in combination, are currently being used in the management of The cumulative number of confirmed COVID-19 cases in South Africa, as at 11 September 2021, was 2 858 195. Contrary to global reports of greater risk of disease among males and older people, female incidence per 100 000 persons was higher than that of males, and the 40-59 age group incidence per 100 000 persons was higher than all age groups. There were 90 174 deaths, equating to 3·2%. (COVID-19 Weekly Epidemiology Brief, 2021) The country experienced three waves, the first peaking in July 2020, the second in January 2021, and the third currently underway as at the time of reporting (National COVID-19 Daily Report, 2021) . The second is predominated by the SARS-CoV-2 501Y.V2 lineage with reportedly higher incidence, hospital admissions, and in-hospital deaths. Patient demographics were also different in that hospitalised individuals were more likely to be older (40-64 years and ≥65 years, compared to <40 years in the first wave) and less likely to have comorbidities. (Jassat et al., 2021) There is minimal information on disease progression, clinical management, and outcomes in COVID-19 patients in hospitals and the community in South Africa. We thus mined the database of the largest public-sector medical insurance scheme in South Africa to analyse the clinical management of COVID-19 in South African private facilities, with a particular emphasis on antimicrobial and steroid therapy, in comparison with the latest WHO and the South African National Institute for Communicable Diseases (NICD) guidelines. We also determined the predictors of mortality in hospitalised patients.

This government employee's medical scheme was established 14 years ago with the intention of improving healthcare coverage to the previously uninsured population and reducing inequities in health coverage. Contributions are income-based, and lower-income earners are fully subsidised by the Government. Pensioners are further defaulted to the lowest contribution band irrespective of their income to ensure adequate financial protection.

This was a retrospective cross-sectional study using claims data of the medical scheme beneficiaries cared for in private facilities in South Africa. All patients with confirmed COVID-19 based on available positive reverse-transcriptase Polymerase Chain Reaction (RT-PCR) results were identified and grouped according to mild-moderate (out-of-hospital care) and severe (in-hospital care) cases. Mild/moderate cases were described as cases that were managed at primary health care, we excluded those who had claims for oxygen. Severe cases were described as cases that were treated in hospital. Criteria for hospital admission is at the discretion of the patient's clinician in the South African private health sector.

Demographics, income levels, clinical, treatment, and pre-existing and co-presenting medical conditions were extracted from member profiles and compared between survivors and nonsurvivors.

We applied univariate and multivariate logistic regression models to explore the risk factors associated with in-hospital death.

Data analysis was carried out using Microsoft Excel and STATA version 16. A descriptive analysis was performed to assess the distribution of patient clinical and demographic characteristics, medication use, hospital characteristics, and clinical outcomes by survival status (deceased vs survived) and treatment setting (outpatient vs inpatient). Categorical variables were expressed as counts and percentages. Continuous data were expressed as median (interquartile range [IQR]) or mean (standard deviation [SD] ). The Mann-Whitney U test, independent t-test, Chi-square test, or Fisher's exact test were used to evaluate differences between groups, as appropriate. Univariate and multivariate logistic regression models were used to explore the risk factors associated with in-hospital mortality, with 28-day mortality as the dependent variable. 46401 (30%) All tests were two-tailed, and all pvalues reported were tested at a α=0·05 level.

The study included 154 519 members of the medical scheme with confirmed SARS-COV-2 infection, of which 66% were female. At least one comorbidity was present in 29% of the participants. Only 36 893 (24%) were treated in hospital. A total of 8 359 (5·4%) people died, and 7 596 (91%) of these deaths occurred in-hospital, translating to an in-hospital rate of 21%. The mean age was 54 and 43, respectively, for in-hospital and out-of-hospital groups.

Hospitalisation was more common in people with one or more comorbidities (38% vs 18%) ( Table 1 ). Only18% of patients treated out of hospital had pneumonia, and 0·1% had ARDS.

Hospitalised patients had the following diagnosis in addition to COVID-19: ARDS (18%), pneumonia (74%), pulmonary embolism (8%), stroke (2·1%), and acute renal failure (ARF) (11%) ( Table 1) .

Among the hospitalised patients, 29% (n=10 607) received oxygen therapy, and 18% (n=6 795) were ventilated. Prescribed medications included antibiotics (43%), antivirals (9%), antifungals (1%), antimalarials (0·4%), and steroids (30%). The steroids were prescribed for all patient categories, i.e. in-hospital (38%) and out-of-hospital (28%). The use of antimicrobial therapy in patients treated in the community was similar to patients treated in hospital. (43% vs 44%), antivirals (9% vs 11%), and antifungals (1% vs 2%) (Table 1) .

Only 44% of in-hospital and 2% of out-of-hospital patients receiving antibiotics were tested using one or more of blood, microscopy, culture and sensitivity (MC&S) tests ( Table 2 ). The antiviral use in 11 000 (73%) patients was associated with chronic antiretroviral medications.

For those who were not on the HIV programme, antivirals include antiretrovirals (11%), oseltamivir (n=1356, 11%), and acyclovir (3%). Antibiotics used include macrolides e.g azithromycin and erythromycin (28%), combinations of amoxicillin and Clavulanic acid, (38%), third-generation cephalosporins (15%), and fluoroquinolones (5%).

We performed univariate logistic regression analyses to investigate possible risk factors associated with COVID-19 in-hospital mortality. We included only the variables significantly associated with mortality in the univariate logistic regression in a multivariate logistic regression model ( 

Of the 154 519 total patients, 24% of patients had appeared to have severe symptoms and were treated in--hospital. Amongst the hospitalised patients, only 47% were put oxygen and/ or ventilation as per the insurance claim. The lower than expected utilisation of oxygen can be ascribed to inappropriate hospitalisation induced by clinicians. The in-hospital case fatality rate was 21%, which was higher than the overall South African in-hospital case fatality rate of 11%. (Jassat et al., 2021) This is because the population included in the study had more access to testing in the private sector than the rest of the population which accessed testing in public sector, and thus more approximate estimation of case fatality rate.

In multivariate analysis, we found that the male gender, age, diabetes, HIV, chronic renal failure and concurrent presentation with heart failure, stroke, pneumonia, and ARDS increased the risk of death. Treatment with antivirals and steroids was associated with reduced mortality. We did not find any significant association between death and income, cancer, coronary artery disease, TB and hypertension.

The male gender is thought to be related to severe COVID-19 outcomes due to overexpression of angiotensin-converting enzyme (ACE) 2 receptors and different immunological responses to the virus. (Aggarwal et al., 2020; Li et al., 2020; Yang et al., 2020) However, males are also known not to seek healthcare and may typically have undiagnosed or uncontrolled comorbidities, such as HIV and diabetes. (Johnson et al., 2015; Kipp et al., 2010) Similar to British (Chedid et al., 2021; Geretti et al., 2020) and other South African studies (Davies, 2020; Jassat et al., 2020) , HIV was associated with increased odds of mortality. However, we noted that use of antiviral therapy, in which 73% of patients received ART as chronic treatment, was associated with lower mortality. Thus it is possible that mortality was high in those HIV positive patients who chose not to take chronic treatment. We did not identify any association between TB and COVID-19 mortality, probably due to the under-representation of TB in these groups, as TB is treated in the public sector.

In our study, we found almost double the odds of death in patients with diabetes. This association is hypothesised to be due to coagulation dysfunction, reduced immune response, and inflammatory response contributing to increased disease severity. In addition, poor access to routine healthcare has been associated with severe outcomes in COVID-19 patients. (Gupta et al., 2020) We did not compare outcomes based on the diabetic control of patients.

Our analysis suggests that ARF and stroke are associated with increased odds of mortality. A similar finding in other studies suggests that the cause of death in COVID-19 patients can be a result of multi-organ failure, which may be as a result of increased levels of inflammatory mediators, endothelial dysfunction, coagulation abnormalities, and infiltration of inflammatory cells into the organs. (Alessandri et al.; Elezkurtaj et al., 2021; Mokhtari et al., 2020) . The aetiology of stroke in the majority of COVID-19 patients has been found to be cryptogenic (undetermined origin) (Ramos-Araque et al., 2021) .

Empiric antimicrobial treatment covering all likely pathogens is recommended on the basis of clinical judgment, patient host factors, and local epidemiology. Antimicrobials should be administered as soon as possible (within 1 hour of initial assessment), ideally with blood cultures obtained first and assessed daily thereafter for de-escalation. However, in our study, antibiotic use was very high, and there was little blood culture testing in out-of-hospital settings. Only 2% of mild/moderate cases of COVID-19 treated out of hospital had microscopy and blood culture. Contrary to the WHO and South African guidelines which recommended against the use of antibiotics (National institute for Communicable Diseases, 2021) , the use of antibiotics was high in this study, even in those who did not have a diagnosis of pneumonia.

The antibiotics used were predominately azithromycin and amoxicillin. The inappropriate use of antibiotics in COVID-19 has not been associated with improved outcomes and instead has been associated with increased risk of allergic reaction and antimicrobial resistance (Chedid et al., 2021; Liu et al., 2021) . Similar to these studies, the use of empirical antibiotic therapy did not reduce the odds of death in hospitalised cases.

Although the South African guidelines recommended the use of steroids only for patients on oxygen supplementation and ventilation, (Chu et al., 2021; National Department of Health, 2020) in this study, we found that steroids were used for COVID-19 patients who did not meet the aforementioned criteria. Use of steroids was associated with a 45% lower mortality rate in patients treated in hospital. A meta-analysis suggests that the use of corticosteroids can delay or even prevent mechanical ventilation, however, inappropriate use can result in delayed viral clearance (van Paassen et al., 2020) . In our study, prednisone, and not dexamethasone was used in 99% of patients. The high utilisation of steroids in the out of hospital setting is concerning.

Use of corticosteroids has been associated with delayed viral clearance.

The inappropriate use of steroids and antimicrobial therapy in this group is largely due to healthcare arrangements in South Africa, where clinicians practising in the private sector have discretion for prescription of medicines, which may be contrary to the national guidelines.

Although TB, hypertension, coronary artery disease, and cancer were associated with increased odds of death in univariate analysis, this was not the case in multivariate analysis. This is contrary to other South African studies. (Jassat et al., 2020) When adjusted for additional risk factors, hypertension alone does not seem to increase the risk of death from COVID-19. (Williamson et al., 2020) The other negative associations could be as a result of the small sample.

The number of people with tuberculosis is underrepresented, as most patients with TB receive treatment from the Government free of charge. (Podestà et al., 2021) The lack of association between CRF and mortality can be a result of high collinearity between diabetes mellitus and CRF.

Unlike other studies (Jung et al., 2021) , we found that the level of income was not a driver of mortality in this insured population. To eliminate differences in care, the Minister of Health amended the Medical Schemes Act Regulations to include COVID-19 as a prescribed minimum benefit, gazetting that all health insurances registered with Council for Medical Schemes in the country cover all individuals irrespective of option plan, contributions, etc. (Medical Schemes Act No.131 OF 1998 , Regulations Amendment, 2020 Therefore gazetting pro-equity legislation eliminated the gaps in access to health care. In addition to the legislation, the mandate of this scheme is to eliminate inequities in access to healthcare through efficient age and income cross-subsidies.

The study relied on claims data for reimbursement. We did not have access to patient records.

The study was also retrospective and cross-sectional, and thus a high risk of misclassification for severity as well as care was possible if the claims were not submitted. Whilst we have assumed that co-presenting conditions are a complications of COVID-19, it is difficult to ascertain temporality in retrospective and cross sectional studies.

The study has shown that comorbidities and concomitant diagnosis with ARF and stroke are associated with a high risk of in-hospital mortality in COVID-19 patients. The highlights inappropriate use of antibiotics in this medically insurance population. South African clinicians should be encouraged to prescribe antimicrobials based on diagnostic stewardship and then only for confirmed secondary bacterial or fungal infections to prevent the unintended consequences of antimicrobial resistance.

Acknowledgements. We thank Ms Jolene Hattingh for her part in editing and support.

Cerebrovascular disease is associated with an increased disease severity in patients with coronavirus disease 2019 (COVID-19): a pooled analysis of published literature

Acute Kidney Injury and COVID-19: A Picture from an Intensive Care Unit

A trial of lopinavir-ritonavir in adults hospitalized with severeCOVID -19

Antibiotic usage in 2019 coronavirus disease (COVID-19) treatment: a rapid review on frequency, indications, and efficacy

Clinical characteristics and outcomes of 48 patients hospitalized for COVID-19 infection in Wuxi: A retrospective cohort study

HIV and risk of COVID-19 death: a population cohort study from the Western Cape Province

Risk factors for SARS

Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. The Lancet Infectious Diseases

Causes of death and comorbidities in hospitalized patients with COVID-19

Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective observational study

Diabetes and COVID-19: evidence, current status and unanswered research questions

COVID-19 in-hospital mortality in South Africa: The intersection of communicable and non-communicable chronic diseases in a high HIV prevalence setting

Increased mortality among individuals hospitalised with COVID-19 during the second wave in South Africa

Coronavirus Resource Centre

Rates of HIV testing and diagnosis in South Africa: successes and challenges

Coronavirus infections and deaths by poverty status: The effects of social distancing

Gender differences in antiretroviral treatment outcomes of HIV patients in rural Uganda

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19

COVID-19 and multiorgan failure: A narrative review on potential mechanisms

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

The Impact of Old and Novel Cardiovascular Risk Factors

Stroke etiologies in patients with COVID-19: the SVIN COVID-19 multinational registry

Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes

Factors associated with COVID-19-related death using OpenSAFELY

Clinical management of COVID-19: interim guidance

Prevalence and impact of acute renal impairment on COVID-19: a systematic review and meta-analysis

The authors declare no competing interests.